Jul 26, 2021 | Anocca in the news
Originally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies...
Jul 22, 2021 | Anocca in the news
Originally published in BioWorld. DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity...
Jul 22, 2021 | Anocca in the news
Originally published in Scrip. SWEDEN-BASED ANOCCA AB WILL USE A just completed $47m Series B financing to advance its industrialised cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells...
Jul 22, 2021 | Anocca in the news
Originally published in Endpoints News. Södertälje, Sweden, the historic home to the Astra half of AstraZeneca, may seem an unlikely place for cutting-edge R&D on T cell receptors and cell therapies. And Reagan Jarvis — a transplant from New Zealand who had...
